Effects of atrovastatin on concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A- reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9) and sortilin in patients with type 2 diabetes mellitus and pre-diabetics
Journal of Nephropathology · 02.07.2020 · 10 (1) · e05-e05
DOI: 10.34172/jnp.2021.05 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nephropathology, online erschienen am 02.07.2020. Verfasst von Ali Nosrati Andevari und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Atorvastatin hinders cardiovascular disease by reducing cholesterol levels. Proprotein convertase subtilisin/kexin type 9 (PCSK9) enhances the secretion of insulin by binding to LDL receptor. Sortilin is committed in the transfer of intracellular proteins through the plasma membrane.
Objectives
The purpose of this research was to determine the effect of atorvastatin consumption on alterations in the levels of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA-R), PCSK9 and sortilin in diabetic patients and pre-diabetics. Patients and Methods: This study was carried out on 80 individuals including normal subjects, diabetic patients and pre-diabetics. The participated individuals were divided as control group (i) (healthy individuals without diabetes mellitus), diabetic group receiving statin (ii), diabetic group not receiving statin (iii), pre-diabetic group receiving statin (iv) and pre-diabetic group not receiving statin (v). Levels of HMG-COA-R, PCSK9 and sortilin were determined by ELISA method.
Results
In diabetics and pre-diabetics taking atorvastatin, the level of HMG-COA-R was not altered significantly compared to diabetics and pre-diabetics not taking atorvastatin, respectively ( P > 0.05). The serum PCSK9 level in diabetics and pre-diabetics was significantly higher than the healthy individuals ( P = 0.001). Additionally, the serum PCSK9 level in diabetics and pre-diabetics receiving atorvastatin was significantly higher than diabetics and pre-diabetics not receiving atorvastatin, respectively ( P =0.001). The serum sortilin level in diabetics and pre-diabetics was significantly higher than the healthy individuals (P=0.001). In addition, the serum sortilin level in pre-diabetics receiving atorvastatin was significantly higher than pre-diabetics not receiving atorvastatin ( P =0.001).
Conclusion
Atorvastatin improved insulin secretion and sensitivity by increasing serum sortilin and PCSK9 levels. Thereby, it prevented the development of diabetes in diabetics and the progression of pre-diabetes to diabetes in pre-diabetics.
Zitieren
APA
Andevari, A. N., Moein, S., Qujeq, D., Moazezi, Z., & Tilaki, K. H. (2020). Effects of atrovastatin on concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A- reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9) and sortilin in patients with type 2 diabetes mellitus and pre-diabetics. Journal of Nephropathology, 10(1), e05-e05. https://doi.org/10.34172/jnp.2021.05
Vancouver
Andevari AN, Moein S, Qujeq D, Moazezi Z, Tilaki KH. Effects of atrovastatin on concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A- reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9) and sortilin in patients with type 2 diabetes mellitus and pre-diabetics. Journal of Nephropathology. 2020;10(1):e05-e05. doi:10.34172/jnp.2021.05
BibTeX
@article{Andevari2020,
author = {Andevari, Ali Nosrati and Moein, Soheila and Qujeq, Durdi and Moazezi, Zoleikha and Tilaki, Karimollah Hajian},
title = {Effects of atrovastatin on concentrations of 3-hydroxy-3-methylglutaryl-coenzyme A- reductase (HMG-CoA-R), proprotein convertase subtilisin/kexin type 9 (PCSK9) and sortilin in patients with type 2 diabetes mellitus and pre-diabetics},
journal = {Journal of Nephropathology},
year = {2020},
volume = {10},
number = {1},
pages = {e05--e05},
doi = {10.34172/jnp.2021.05}
}
EUVIMED